Legato Capital Management LLC Acquires 12,961 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Legato Capital Management LLC raised its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 88.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,691 shares of the company’s stock after buying an additional 12,961 shares during the period. Legato Capital Management LLC’s holdings in GeneDx were worth $2,128,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. MCF Advisors LLC lifted its position in GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. CWM LLC purchased a new stake in shares of GeneDx in the third quarter worth approximately $89,000. SG Americas Securities LLC bought a new position in shares of GeneDx in the third quarter valued at approximately $198,000. Evolution Wealth Advisors LLC purchased a new position in shares of GeneDx during the fourth quarter valued at approximately $202,000. Finally, Point72 DIFC Ltd bought a new stake in GeneDx during the third quarter worth $220,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Stock Down 0.5 %

NASDAQ WGS opened at $67.80 on Wednesday. The business’s fifty day moving average is $76.62 and its 200-day moving average is $59.99. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a one year low of $3.86 and a one year high of $98.87.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. The Goldman Sachs Group raised their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Craig Hallum boosted their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company increased their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $70.67.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the completion of the transaction, the chief executive officer now owns 3,937 shares in the company, valued at approximately $308,975.76. This represents a 29.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of GeneDx stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $70.78, for a total value of $8,973,629.96. Following the completion of the sale, the insider now directly owns 2,719,692 shares of the company’s stock, valued at approximately $192,499,799.76. This trade represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 363,669 shares of company stock worth $28,061,081. Insiders own 27.30% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.